IL1RAPL1 (Q9NZN1) variants and mutations
IL1RAPL1 (also known as Q9NZN1) is a human protein-coding gene encoding an interleukin-1 receptor accessory protein-like 1 protein. A neuronal cell-surface protein involved in synapse organization and signaling. Disrupting its function is associated with neurodevelopmental conditions, including X-linked intellectual disability. This analysis covers 655 IL1RAPL1 variants and mutations. Of these, 99% have computational variant effect predictions. Disease context includes intellectual disability, X-linked 21, X-linked non-syndromic intellectual disability, and non-syndromic X-linked intellectual disability. Example IL1RAPL1 variants include A3T, A3V, and A3D.
Variant analysis overview
- Gene: IL1RAPL1
- Protein: Q9NZN1
- UniProt accession: Q9NZN1
- Organism: Homo sapiens
- Variants analyzed: 655
- Variant scope: all variants
- Completed: 2026-09-21
Variant and mutation evidence
- Variant composition: 634 unspecified-consequence records; 98 missense variants; 87 synonymous variants; 4 frameshift variants; 6 splice-region variants; 1 in-frame deletions; 4 stop-gained variants; 1 substitution
- Prediction scores: 647 variants have prediction scores (99% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: intellectual disability, X-linked 21, X-linked non-syndromic intellectual disability, non-syndromic X-linked intellectual disability, hereditary disease, Intellectual disability, schizophrenia, severe acute respiratory syndrome, COVID-19, ventral hernia, vitiligo, developmental disability, neoplasm.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 4 domains; 6 post-translational modification sites.
- Structural context: 484 variants have structural context.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable IL1RAPL1 variants
Examples include A3T, A3V, A3D, P4A, P4L, P4S, P4P, P6P. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A3T (p.Ala3Thr), NCI-TCGA Cosmic COSV5624, Variant assessed as somatic; high impact.
- A3V (p.Ala3Val), ExAC rs767260893, gnomAD rs767260893, REVEL 0.09, CADD 17.00
- A3D (p.Ala3Asp), gnomAD X-28789351-C-A, REVEL 0.13, CADD 19.80
- P4A (p.Pro4Ala), ESP rs148886996, gnomAD rs148886996, MetaLR 0.01, MetaSVM -1.01
- P4L (p.Pro4Leu), rs773334103, ClinGen CA10375350, ClinVar RCV002938571, ExAC rs773334103, REVEL 0.10, CADD 20.60, Benign/Likely benign, not provided
- P4S (p.Pro4Ser), ESP rs148886996, gnomAD rs148886996, REVEL 0.16, CADD 19.90
- P4P (p.Pro4Pro), rs143600441, gnomAD X-28789355-G-A, CADD 5.76
- P6P (p.Pro6Pro), gnomAD X-28789361-A-T, CADD 4.69
- H7L (p.His7Leu), Ensembl rs1025178079, MetaLR 0.00, MetaSVM -1.00
- H7R (p.His7Arg), gnomAD X-28789363-A-G, REVEL 0.20, CADD 22.40
- H7H (p.His7His), rs765572976, gnomAD X-28789364-C-T, CADD 7.15
- L8M (p.Leu8Met), TOPMed rs1277288105, MetaLR 0.02, MetaSVM -0.98
- L8W (p.Leu8Trp), ExAC rs750663388, gnomAD rs750663388, REVEL 0.22, CADD 25.00
- I9V (p.Ile9Val), rs2518875104, ClinGen CA412631843, ClinVar RCV003695449, REVEL 0.06, CADD 16.20, Uncertain significance, not provided
- I9S (p.Ile9Ser), gnomAD X-28789369-T-G, REVEL 0.16, CADD 23.50
- Y12H (p.Tyr12His), gnomAD rs1306600004, MetaLR 0.01, MetaSVM -0.83
- Y12C (p.Tyr12Cys), gnomAD X-28789378-A-G, REVEL 0.26, CADD 22.30
- Y12Y (p.Tyr12Tyr), rs148060509, gnomAD X-28789379-C-T, CADD 5.58
- A13S (p.Ala13Ser), rs1240596680, NCI-TCGA Cosmic COSV1001, TOPMed rs1240596680, gnomAD rs1240596680, AlphaMissense 0.09, MetaLR 0.01, Variant assessed as somatic; moderate impact.
- A13T (p.Ala13Thr), TOPMed rs1240596680, gnomAD rs1240596680, REVEL 0.18, CADD 21.50
- A13D (p.Ala13Asp), gnomAD X-28789381-C-A, REVEL 0.12, CADD 20.80
- A13A (p.Ala13Ala), gnomAD X-28789382-T-C, CADD 11.00
- T14A (p.Thr14Ala), ExAC rs780153399, gnomAD rs780153399, REVEL 0.21, CADD 18.40
- T14I (p.Thr14Ile), gnomAD X-28789384-C-T, REVEL 0.26, CADD 19.30
- T16T (p.Thr16Thr), rs747519073, gnomAD X-28789391-T-G, CADD 8.23
- Q17R (p.Gln17Arg), gnomAD X-28789393-A-G, REVEL 0.24, CADD 18.90
- Q17H (p.Gln17His), gnomAD X-28789394-G-C, REVEL 0.11, CADD 18.40
- S18G (p.Ser18Gly), NCI-TCGA Cosmic COSV5626, NCI-TCGA Cosmic COSV9904, TOPMed rs1936510256, REVEL 0.19, CADD 19.90, Variant assessed as somatic; moderate impact.
- L19F (p.Leu19Phe), Ensembl rs2147265225
- L19V (p.Leu19Val), 1000Genomes rs775646594, ExAC rs775646594, gnomAD rs775646594, REVEL 0.20, CADD 17.10
- K20R (p.Lys20Arg), rs781634327, ClinGen CA10375358, ClinVar RCV003993051, ExAC rs781634327, REVEL 0.23, CADD 22.50, Benign/Likely benign, not provided
- K20K (p.Lys20Lys), rs748516132, gnomAD X-28789403-G-A, CADD 7.83
- V21A (p.Val21Ala), TOPMed rs1330799870, gnomAD rs1330799870, NCI-TCGA Cosmic COSV5627, REVEL 0.20, CADD 20.80, Variant assessed as somatic; moderate impact.
- V21F (p.Val21Phe), rs1936510432, ClinGen CA412631926, ClinVar RCV001093396, Ensembl rs1936510432, REVEL 0.23, CADD 20.10, Uncertain significance, not provided
- V22G (p.Val22Gly), gnomAD X-28789408-T-G, REVEL 0.27, CADD 23.90
- V22V (p.Val22Val), gnomAD X-28789409-G-T, CADD 7.14
- T23G (p.Thr23Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T23T (p.Thr23Thr), gnomAD X-28789412-C-A, CADD 9.44
- K24Q (p.Lys24Gln), Ensembl rs1601904286, MetaLR 0.02, MetaSVM -1.03
- R25E (p.Arg25Glu), gnomAD X-28789412-CA-C, CADD 31.00
- G26A (p.Gly26Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G26S (p.Gly26Ser), gnomAD rs1236580645, REVEL 0.18, CADD 21.20
- G26G (p.Gly26Gly), gnomAD X-28789421-C-A, CADD 7.99
- S27P (p.Ser27Pro), TOPMed rs1936510609, MetaLR 0.02, MetaSVM -1.07, Uncertain significance, not provided
- S27F (p.Ser27Phe), gnomAD X-28789423-C-T, REVEL 0.23, CADD 25.10
- S27S (p.Ser27Ser), rs1033929254, gnomAD X-28789424-C-T, CADD 13.20
- A28T (p.Ala28Thr), rs377167082, ClinGen CA10375360, NCI-TCGA Cosmic COSV5627, ClinVar RCV003133700, REVEL 0.18, CADD 26.40, Conflicting interpretations, not provided; Intellectual disability, X-linked 21
- A28A (p.Ala28Ala), rs773998745, gnomAD X-29282939-C-T, CADD 10.50
- D29N (p.Asp29Asn), rs763980117, NCI-TCGA Cosmic COSV5631, ExAC rs763980117, gnomAD rs763980117, REVEL 0.18, CADD 26.70, Variant assessed as somatic; moderate impact.
- D29V (p.Asp29Val), ExAC rs750716100, TOPMed rs750716100, gnomAD rs750716100, REVEL 0.41, CADD 25.80
- D29Y (p.Asp29Tyr), gnomAD X-29282940-G-T, REVEL 0.43, CADD 27.00
- G30G (p.Gly30Gly), rs758626848, gnomAD X-29282945-A-G, CADD 11.10
- C31A (p.Cys31Ala), NCI-TCGA Cosmic COSV1001, NCI-TCGA Cosmic COSV5625, Variant assessed as somatic; moderate impact.
- C31G (p.Cys31Gly), NCI-TCGA Cosmic COSV1001, NCI-TCGA Cosmic COSV5625, Variant assessed as somatic; moderate impact.
- C31C (p.Cys31Cys), gnomAD X-29282948-C-T, CADD 9.38
- T32T (p.Thr32Thr), rs201738392, gnomAD X-29282951-T-C, CADD 1.87
- I36V (p.Ile36Val), rs369272343, ExAC rs369272343, TOPMed rs369272343, gnomAD rs369272343, REVEL 0.09, CADD 10.60, Variant assessed as somatic; moderate impact.
- I36I (p.Ile36Ile), rs947463334, gnomAD X-29282963-C-T, CADD 1.13
- D37D (p.Asp37Asp), gnomAD X-29282966-T-C, CADD 8.31
- K39R (p.Lys39Arg), TOPMed rs1043539585, gnomAD rs1043539585, REVEL 0.25, CADD 19.80
- K39K (p.Lys39Lys), gnomAD X-29282972-G-A, CADD 9.26
- Y41Y (p.Tyr41Tyr), rs145006320, gnomAD X-29282978-T-C, CADD 2.30
- L44L (p.Leu44Leu), gnomAD X-29282985-T-C, CADD 10.30
- V45A (p.Val45Ala), gnomAD X-29282989-T-C, REVEL 0.23, CADD 17.70
- G46E (p.Gly46Glu), rs1293643963, ClinVar RCV004593476, gnomAD rs1293643963, REVEL 0.90, CADD 25.90, Uncertain significance, not provided
- G46R (p.Gly46Arg), rs868613900, ClinGen CA328232579, ClinVar RCV000498869, ClinVar RCV005851554, REVEL 0.90, CADD 26.90, Uncertain significance, not provided; Inborn genetic diseases
- G46G (p.Gly46Gly), gnomAD X-29282993-A-G, CADD 12.10
- P48P (p.Pro48Pro), gnomAD X-29282999-T-C, CADD 11.70
- V49I (p.Val49Ile), gnomAD X-29283000-G-A, REVEL 0.31, CADD 23.40
- V49A (p.Val49Ala), gnomAD X-29283001-T-C, REVEL 0.48, CADD 22.60
- R50* (p.Arg50Ter), rs781674023, ClinGen CA412632964, NCI-TCGA Cosmic COSV5623, ClinVar RCV001814756, CADD 35.00, Pathogenic
- R50G (p.Arg50Gly), rs781674023, ClinGen CA10375377, ClinVar RCV002749957, ExAC rs781674023, REVEL 0.61, CADD 24.00, Uncertain significance, Inborn genetic diseases
- R50Q (p.Arg50Gln), rs199864130, NCI-TCGA Cosmic COSV5625, ESP rs199864130, ExAC rs199864130, REVEL 0.54, CADD 28.40, Benign, not provided
- I51M (p.Ile51Met), Ensembl rs1932226932, REVEL 0.42, CADD 23.30, Uncertain significance, Inborn genetic diseases
- I51V (p.Ile51Val), gnomAD X-29283006-A-G, REVEL 0.24, CADD 17.20
- K52K (p.Lys52Lys), gnomAD X-29283011-A-G, CADD 9.11
- C53G (p.Cys53Gly), NCI-TCGA Cosmic COSV5628, Variant assessed as somatic; moderate impact.
- A54V (p.Ala54Val), TOPMed rs1932227016, gnomAD rs1932227016, REVEL 0.57, CADD 25.30, Uncertain significance, not provided
- L55L (p.Leu55Leu), rs756536212, gnomAD X-29283020-C-T, CADD 6.82
- Y57C (p.Tyr57Cys), gnomAD X-29283025-A-G, REVEL 0.69, CADD 26.80
- Y57Y (p.Tyr57Tyr), gnomAD X-29283026-T-C, CADD 4.95
- I60M (p.Ile60Met), TOPMed rs1189623507, MetaLR 0.49, MetaSVM -0.04
- I60V (p.Ile60Val), gnomAD X-29283033-A-G, REVEL 0.40, CADD 23.30
- R61K (p.Arg61Lys), gnomAD X-29283037-G-A, REVEL 0.37, CADD 22.70
- T62A (p.Thr62Ala), NCI-TCGA Cosmic COSV5630, MetaLR 0.53, MetaSVM 0.01, Variant assessed as somatic; high impact.
- N63D (p.Asn63Asp), Ensembl rs2147599962, MetaLR 0.60, MetaSVM 0.22
- S65S (p.Ser65Ser), gnomAD X-29283050-C-A, CADD 7.31
- A67A (p.Ala67Ala), rs1932227260, gnomAD X-29283056-C-G, CADD 8.75
- Q68L (p.Gln68Leu), ExAC rs778076494, gnomAD rs778076494, REVEL 0.67, CADD 25.40
- Q68R (p.Gln68Arg), ExAC rs778076494, gnomAD rs778076494, MetaLR 0.53, MetaSVM -0.03
- S69I (p.Ser69Ile), ExAC rs747458852, TOPMed rs747458852, gnomAD rs747458852, REVEL 0.44, CADD 25.70, Uncertain significance
- S69N (p.Ser69Asn), rs747458852, ClinGen CA10646104, ClinVar RCV000335751, ExAC rs747458852, REVEL 0.13, CADD 21.30, Uncertain significance, Intellectual disability, X-linked 21
- S69T (p.Ser69Thr), ExAC rs747458852, TOPMed rs747458852, gnomAD rs747458852, REVEL 0.22, CADD 24.50, Uncertain significance
- G71R (p.Gly71Arg), TOPMed rs1006110350, gnomAD rs1006110350, REVEL 0.41, CADD 26.70
- G71T (p.Gly71Thr), NCI-TCGA Cosmic COSV1001, MetaLR 0.57, MetaSVM 0.09, Variant assessed as somatic; moderate impact.
- G71G (p.Gly71Gly), rs1569276602, gnomAD X-29283068-A-C, CADD 7.72
- L72L (p.Leu72Leu), rs773831867, gnomAD X-29283071-C-T, CADD 9.13
- S73I (p.Ser73Ile), gnomAD X-29283073-G-T, REVEL 0.39, CADD 25.70
- Y77* (p.Tyr77Ter), ExAC rs771699827, TOPMed rs771699827
- Y77Y (p.Tyr77Tyr), rs771699827, gnomAD X-29283086-C-T, CADD 6.77
- K78R (p.Lys78Arg), rs138853476, ClinGen CA10375386, ClinVar RCV002628184, ClinVar RCV004070554, REVEL 0.22, CADD 17.50, Uncertain significance, Inborn genetic diseases; not provided
- K78K (p.Lys78Lys), rs760659039, gnomAD X-29283089-A-G, CADD 9.39
- S79I (p.Ser79Ile), gnomAD rs1228304498, REVEL 0.34, CADD 23.20
- S79V (p.Ser79Val), rs1569276612, gnomAD X-29283086-CA-C, CADD 26.70
- S79N (p.Ser79Asn), gnomAD X-29283091-G-A, REVEL 0.20, CADD 19.60
- G81D (p.Gly81Asp), ExAC rs768623221, gnomAD rs768623221, REVEL 0.31, CADD 23.40
- P82A (p.Pro82Ala), TOPMed rs1203933310, REVEL 0.13, CADD 21.70
- E87D (p.Glu87Asp), rs1030366729, ClinGen CA328232595, ClinVar RCV002603199, ClinVar RCV003250787, REVEL 0.39, CADD 21.50, Conflicting interpretations, Inborn genetic diseases; not provided; not specified
- P88P (p.Pro88Pro), rs1932228416, gnomAD X-29283119-A-T, CADD 6.92
- I89V (p.Ile89Val), gnomAD rs1932228497, REVEL 0.35, CADD 24.30
- A90V (p.Ala90Val), gnomAD rs1211935454, REVEL 0.20, CADD 20.50
- A90G (p.Ala90Gly), NCI-TCGA Cosmic COSV5623, MetaLR 0.62, MetaSVM 0.30, Variant assessed as somatic; moderate impact.
- F91S (p.Phe91Ser), gnomAD X-29283127-T-C, REVEL 0.68, CADD 27.00
- D92D (p.Asp92Asp), rs771532815, gnomAD X-29283131-C-T, CADD 8.22
- G93A (p.Gly93Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G93T (p.Gly93Thr), NCI-TCGA TCGA novel, MetaLR 0.32, MetaSVM -0.52, Variant assessed as somatic; moderate impact.
- G93R (p.Gly93Arg), TOPMed rs865917918, gnomAD rs865917918, REVEL 0.41, CADD 26.80, Uncertain significance, not provided
- R95R (p.Arg95Arg), rs776507908, gnomAD X-29283138-A-C, CADD 10.70
- M96I (p.Met96Ile), gnomAD rs1192090889, REVEL 0.33, CADD 17.40
- S97I (p.Ser97Ile), gnomAD X-29283145-G-T, REVEL 0.58, CADD 24.10
- E99G (p.Glu99Gly), TOPMed rs1234107078, gnomAD rs1234107078, REVEL 0.59, CADD 27.30
- E99K (p.Glu99Lys), gnomAD X-29283150-G-A, REVEL 0.49, CADD 27.70
- E99Q (p.Glu99Gln), gnomAD X-29283150-G-C, REVEL 0.40, CADD 26.00
- E100D (p.Glu100Asp), gnomAD rs1177211363, REVEL 0.33, CADD 15.10
- E100del (p.Glu100del), rs1266037254, gnomAD X-29283147-AAAG-A, CADD 19.30
- D101N (p.Asp101Asn), gnomAD X-29283156-G-A, REVEL 0.40, CADD 27.40
- S102P (p.Ser102Pro), gnomAD X-29283159-T-C, REVEL 0.53, CADD 22.70
- S102S (p.Ser102Ser), rs954773005, gnomAD X-29283161-C-T, CADD 8.20
- I103V (p.Ile103Val), rs1355268343, ClinGen CA412633335, ClinVar RCV003554604, TOPMed rs1355268343, REVEL 0.54, CADD 21.20, Uncertain significance, not provided
- F105L (p.Phe105Leu), NCI-TCGA TCGA novel, gnomAD rs1186311560, MetaLR 0.40, MetaSVM -0.20, Variant assessed as somatic; moderate impact.
- R106Q (p.Arg106Gln), rs751673587, ClinGen CA10375392, NCI-TCGA Cosmic COSV5624, ClinVar RCV003342437, REVEL 0.56, CADD 27.50, Conflicting interpretations, not provided; Inborn genetic diseases
- R106W (p.Arg106Trp), rs766627012, NCI-TCGA Cosmic COSV5626, ExAC rs766627012, TOPMed rs766627012, REVEL 0.56, CADD 23.60, Variant assessed as somatic; moderate impact.
- P107A (p.Pro107Ala), NCI-TCGA TCGA novel, Ensembl rs1602150680, MetaLR 0.47, MetaSVM -0.24, Variant assessed as somatic; moderate impact.
- T108A (p.Thr108Ala), TOPMed rs1311064552
- T108I (p.Thr108Ile), TOPMed rs1393447066
- T108S (p.Thr108Ser), TOPMed rs1311064552, MetaLR 0.33, MetaSVM -0.34
- L109L (p.Leu109Leu), gnomAD X-29283180-T-C, CADD 8.03
- L110L (p.Leu110Leu), rs1422534109, gnomAD X-29283185-A-G, CADD 4.38
- Q111H (p.Gln111His), gnomAD rs1185867220, REVEL 0.34, CADD 20.70
- Q111K (p.Gln111Lys), gnomAD X-29283186-C-A, REVEL 0.21, CADD 22.30
- D112G (p.Asp112Gly), rs759718387, NCI-TCGA Cosmic COSV1001, ExAC rs759718387, gnomAD rs759718387, AlphaMissense 1.00, MetaLR 0.79, Variant assessed as somatic; moderate impact.
- D112E (p.Asp112Glu), gnomAD X-29283191-C-G, REVEL 0.71, CADD 23.10
- S113G (p.Ser113Gly), ExAC rs767578324, gnomAD rs767578324, REVEL 0.38, CADD 22.50
- S113S (p.Ser113Ser), rs753240400, gnomAD X-29283194-T-C, CADD 4.60
- G114A (p.Gly114Ala), NCI-TCGA TCGA novel, MetaLR 0.21, MetaSVM -0.98, Variant assessed as somatic; moderate impact.
- L115V (p.Leu115Val), gnomAD X-29283198-C-G, REVEL 0.18, CADD 15.10
- Y116D (p.Tyr116Asp), gnomAD X-29283201-T-G, REVEL 0.93, CADD 25.10
- Y116Y (p.Tyr116Tyr), rs771224987, gnomAD X-29283203-C-T, CADD 0.04
- A117S (p.Ala117Ser), ExAC rs778199033, TOPMed rs778199033, gnomAD rs778199033, REVEL 0.26, CADD 18.70, Uncertain significance, Inborn genetic diseases
- A117T (p.Ala117Thr), rs778199033, ClinGen CA10375397, NCI-TCGA Cosmic COSV5626, ClinVar RCV002214519, REVEL 0.31, CADD 16.30, Conflicting interpretations, not provided
- A117C (p.Ala117Cys), NCI-TCGA Cosmic COSV1001, Variant assessed as somatic; moderate impact.
- V119F (p.Val119Phe), rs2518997867, ClinVar RCV004588830, Uncertain significance, not provided
- I120L (p.Ile120Leu), Ensembl rs1932230522, MetaLR 0.14, MetaSVM -0.81
- I120V (p.Ile120Val), gnomAD X-29283213-A-G, REVEL 0.24, CADD 22.10
- S123S (p.Ser123Ser), gnomAD X-29396264-C-A, CADD 7.49
- T124N (p.Thr124Asn), gnomAD X-29396266-C-A, REVEL 0.62, CADD 24.40
- Y125* (p.Tyr125Ter), rs1933918055, ClinGen CA412632030, ClinVar RCV002512402, CADD 35.00, Likely pathogenic
- Y125Y (p.Tyr125Tyr), rs1933918055, gnomAD X-29396270-C-T, CADD 5.46
- C126R (p.Cys126Arg), rs2519091682, ClinGen CA412632032, ClinVar RCV003159470, Uncertain significance, not provided
- M127V (p.Met127Val), gnomAD X-29396274-A-G, REVEL 0.55, CADD 23.30
- K128K (p.Lys128Lys), gnomAD X-29396279-A-G, CADD 7.78
- I131V (p.Ile131Val), gnomAD X-29396286-A-G, REVEL 0.25, CADD 22.80
- S132* (p.Ser132Ter), gnomAD X-29396290-C-A, CADD 36.00
- S132S (p.Ser132Ser), gnomAD X-29396291-A-C, CADD 1.54
- L133L (p.Leu133Leu), rs1017513669, gnomAD X-29396292-C-T, CADD 9.47
- T134G (p.Thr134Gly), NCI-TCGA TCGA novel, MetaLR 0.43, MetaSVM -0.23, Variant assessed as somatic; moderate impact.
- T134I (p.Thr134Ile), gnomAD X-29396296-C-T, REVEL 0.47, CADD 18.50
- G136T (p.Gly136Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G136S (p.Gly136Ser), gnomAD X-29396301-G-A, REVEL 0.28, CADD 21.50
- G136D (p.Gly136Asp), gnomAD X-29396302-G-A, REVEL 0.29, CADD 21.90
- G136G (p.Gly136Gly), rs1397912387, gnomAD X-29396303-T-C, CADD 4.54
- E137V (p.Glu137Val), ExAC rs754291200, gnomAD rs754291200, REVEL 0.71, CADD 24.30
- N138S (p.Asn138Ser), TOPMed rs1376529615, gnomAD rs1376529615, REVEL 0.14, CADD 19.50
- D139N (p.Asp139Asn), rs1238348693, ClinGen CA412632120, ClinVar RCV001550348, ClinVar RCV004988679, REVEL 0.24, CADD 24.10, Conflicting interpretations, not provided; Inborn genetic diseases
- D139V (p.Asp139Val), TOPMed rs964006475, MetaLR 0.02, MetaSVM -1.06
- D139G (p.Asp139Gly), gnomAD X-29396311-A-G, REVEL 0.45, CADD 23.80
- D139D (p.Asp139Asp), rs1311939495, gnomAD X-29396312-C-T, CADD 8.31
- T140I (p.Thr140Ile), Ensembl rs940456912, MetaLR 0.02, MetaSVM -0.97
- G141T (p.Gly141Thr), NCI-TCGA Cosmic COSV5626, MetaLR 0.04, MetaSVM -1.11, Variant assessed as somatic; moderate impact.
- G141A (p.Gly141Ala), gnomAD X-29396317-G-C, REVEL 0.11, CADD 21.40
Public IL1RAPL1 analysis runs
- IL1RAPL1 analysis run — IL1RAPL1 (655 variants) — completed 2026-09-21